October 2014 | OncologyLive

Chasing CTCs: Novel Technologies May Unlock Potential of Elusive Biomarker

October 28, 2014

Despite being discovered more than 150 years ago, tumor cells present in the blood of patients with cancer are only now inspiring significant research efforts. Technological advancements have allowed the isolation and enrichment of these rare cells and, as potential metastatic "emissaries," they have significant potential for improving the detection and treatment of advanced and possibly even early-stage disease.

Rini Discusses Variable Impact of Angiogenesis in Solid Tumors

October 13, 2014

Rini, who is a professor at the Cleveland Clinic Lerner College of Medicine in addition to holding several posts at the Case Comprehensive Cancer Center, discussed broad issues in antiangiogenic research in this interview with OncologyLive.

Attacking Angiogenesis Anew: Novel Agents and Strategies Keep Focus on Complex Cancer Hallmark

October 10, 2014

A decade after bevacizumab (Avastin) debuted as the first anticancer therapy to target angiogenesis, new strategies to attack this hallmark of cancer continue to be a major research focus, resulting in the development of novel agents and fresh treatment settings for existing drugs.

Petrylak Anticipates Bright Future for PD-L1 Inhibitors in Bladder Cancer

October 09, 2014

Checkpoint inhibitors targeting the PD-1 receptor and its ligand, PD-L1, are showing efficacy in early-phase clinical trials in urothelial bladder cancer, generating the promise of new therapies for a disease that has not had a significant treatment advance in 30 years.

Taking a Value-Based Approach to Breast Cancer Screening, Workup, and Surveillance

October 02, 2014

It is well known that healthcare spending in the United States is unsustainable. It is also well known that despite spending a record $2.8 trillion on healthcare annually (17.2% of GDP in 2012)-more than any other nation-our health outcomes lag behind.

EGFR Pioneer Keeps Focus on Individualizing Patient Care in Lab and Clinic

October 01, 2014

As director of the Yale Cancer Center and physician-in-chief of the Smilow Cancer Hospital at Yale-New Haven, Thomas J. Lynch Jr, MD, wears many hats. And, having built a career united around two abiding goals of clinical discovery and personalized patient care, that's just the way he likes it.